iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorSynbiotic Health
About this trial
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.
Eligibility criteria
Qualifiers
Aged 40-75 years.
BMI: 20-34.9 kg/m².
Able and willing to sign informed consent and participate for the study duration.
Disqualifiers
Chronic disease history (liver, kidney, heart).
Current pregnancy and/or lactating.
Colonoscopy and/or its preparation within 4 weeks of screening.
Those who intend to have children during study period.
Trial design
Treatments tested in this trial
- Bifidobacterium adolescentis iVS-1
- Placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Synbiotic Health
Lead sponsor
MusB Research
Collaborator
Source ClinicalTrials.gov